Achilles Therapeutics is biopharmaceutical company developing novel cancer immunotherapies targeting clonal neoantigens. It is a spinout from Cancer Research UK. Achilles develop personalized cell therapies using individual DNA sequencing data and proprietary bioinformatics platform. Targeting multiple clonal neoantigens that are present only on all cancer cells, allows individualised treatments to target and destroy tumours without harming healthy tissues.